MedTrace Logo

Lithium in Inclusion Body Myositis (IBM)

NCT00917956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2010-02-26

No results posted yet for this study

Summary

IBM is the most common acquired muscle disease occurring over the age of 50. The underlying cause remains unknown and there is currently no effective treatment. Pathological studies have revealed abnormal collections of proteins in the muscle cells from patients with IBM. These include proteins called phosphorylated tau (p-tau). A similar process appears to occur in Alzheimer disease, with accumulations of p-tau developing in brain cells. Lithium decreases the activity of the GSK, an enzyme that has a key role in the development of p-tau. Lithium and other GSK inhibitors have been shown to decrease the accumulation of p-tau in nerve cells in animal models of Alzheimer disease. The proposed research is a pilot study to see if lithium might be an effective treatment for IBM

Conditions

  • Inclusion Body Myositis

Sponsors & Collaborators

  • Phoenix Neurological Associates, LTD

    lead OTHER

Principal Investigators

  • David D Saperstein, MD · Phoenix Neurological Associates, LTD

Eligibility

Min Age
30 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917956 on ClinicalTrials.gov